| 영문 | dopamine | 한글 | 도파민 |
|---|---|---|---|
| 설명 | 히드록시티라민으로서 생리활성 아민-카테콜아민의 일종. 분자식은C18H11NO2, 분자량은 153.18이다. 동식물에 존재하는 아미노산의 하나로, 자외선 작용으로 티로신에서 형성되거나 L-Dopa의 탈탄산에 의해 체내에서 생산된다. 멜라닌 색소 합성 과정의 중간 물질로 콩과 식물에 저장되어 있다. 뇌신경 세포의 흥분 전달에 중요한 구실을 한다. 도파민β-산화효소의 작용에 의해 노르아드레날린이 된다. 부신수질-뇌-교감신경계-폐-작은창자-간 등에도 많이 포함되어 있다. 파킨슨 증후군의 경우 뇌 안의 도파민 량이 감소되며, 뇌줄기의 줄무늬체에는 노르아드레날린보다 도파민이 다량 포함되어 있음을 볼 수 있다는 점에서 도파민 자체가 이른바 카테콜아민을 함유하는 작동성 뉴런의 신경전달물질로서 작용하고 있음이 분명해졌다. |
||
| 영문 | agonist | 한글 | 작용제, 작용근 |
|---|---|---|---|
| 설명 | 1. 수용체와 결합하여 최대의 약리작용을 발현하는 화학물질을 말한다. 수용체에 특이하게 친화성을 가지고 있다. 생체 안에서 생산되는 내인성인 것과 생체 밖에서 투여되는 외인성인 것이 있다. 부분 작용제는 수용체와 결합해도 100%의 약리작용을 발현하지는 않으며 용량을 증가시켜도 효과는 커지지 않는다. 2. 해부학에서는 주가 되어 움직이는 근육의 무리 |
||
| IHSS(= HCMP) | Idiopathic Hypertrophic Subaortic Stenosis = Obstructive Idiopathic Hypertrophic Car... |
|---|---|
| ORA | opiate receptor agonist |
| PAA | partial agonist activity; phenylacetic acid; phosphonoacetic acid; physical abilities analysis; plas... |
| DBH | Dopamine-Beta(β)-Hydroxylase |
| DA | dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis... |
| R,S | receptor agonist |
|---|---|
| 8-OH-DPAT | 5-HT agonist 8-hydroxy-2-(di-n-propylamino) tetralin |
| 8-OH-DPAT | 5-HT(1A) receptor agonist, 8-hydroxy 2(di-n-propyl(amino)tetralin |
| (35)S | Agonist-stimulated |
| GNRH-a | GnRH agonist |
striate body neurosis
| agonist | 1. <anatomy> A prime mover. 2. <pharmacology> A drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances, thus triggering a biochemical response. (18 Nov 1997) |
|---|---|
| calcium channel agonist | <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. (12 Dec 1998) |
| receptor agonist | A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted. (22 May 1997) |
| mixed opioid agonist-antagonist | <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type. (13 Nov 1997) |
| muscarinic agonist | Drugs that bind to and activate muscarinic cholinergic receptors (receptors, muscarinic). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (12 Dec 1998) |
| histamine agonist | Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (12 Dec 1998) |
| opioid agonist | <pharmacology> Any morphine-like compound that produces bodily effects including pain relief, sedation, constipation and respiratory depression. (16 Dec 1997) |
| opioid partial agonist | <pharmacology> A compound that has an affinity for and stimulates physiologic activity at the same cell receptors as opioid agonists but that produces only a partial (i.e., submaximal) bodily response. (16 Dec 1997) |
| LH and RH agonist | <pharmacology> Particular medications that act as potent inhibitors of gonadotrophin (testosterone) secretion. They act to inhibit the production of testosterone through a feedback mechanism on the pituitary gland. LH and RH agonists are useful in the treatment of prostate cancer. (14 Oct 1997) |
| receptors, dopamine | Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behaviour of cells. (12 Dec 1998) |
| receptors, dopamine d1 | A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, by their mode of action. (12 Dec 1998) |
| receptors, dopamine d2 | A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, their mode of action. (12 Dec 1998) |
| dopamine | <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline. Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min. Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias (15 Mar 2000) |
| dopamine agents | Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (12 Dec 1998) |
| dopamine agonists | Drugs that bind to and activate dopamine receptors. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|